DE602007010038D1 - Pyrimidylderivate als proteinkinaseinhibitoren - Google Patents

Pyrimidylderivate als proteinkinaseinhibitoren

Info

Publication number
DE602007010038D1
DE602007010038D1 DE602007010038T DE602007010038T DE602007010038D1 DE 602007010038 D1 DE602007010038 D1 DE 602007010038D1 DE 602007010038 T DE602007010038 T DE 602007010038T DE 602007010038 T DE602007010038 T DE 602007010038T DE 602007010038 D1 DE602007010038 D1 DE 602007010038D1
Authority
DE
Germany
Prior art keywords
kinininhibitors
protein
pyrimidine derivatives
compounds
above compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007010038T
Other languages
English (en)
Inventor
Guy Georges
Matthias Koerner
Irene Kolm
Ulrike Reiff
Wolfgang Schaefer
Edgar Voss
Stefan Weigand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602007010038D1 publication Critical patent/DE602007010038D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
DE602007010038T 2006-12-22 2007-12-19 Pyrimidylderivate als proteinkinaseinhibitoren Active DE602007010038D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06026650 2006-12-22
PCT/EP2007/011161 WO2008077548A1 (en) 2006-12-22 2007-12-19 Pyrimidyl derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
DE602007010038D1 true DE602007010038D1 (de) 2010-12-02

Family

ID=38038715

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007010038T Active DE602007010038D1 (de) 2006-12-22 2007-12-19 Pyrimidylderivate als proteinkinaseinhibitoren

Country Status (14)

Country Link
US (1) US8080552B2 (de)
EP (1) EP2102173B1 (de)
JP (1) JP2010507573A (de)
KR (1) KR101131400B1 (de)
CN (1) CN101541766B (de)
AT (1) ATE485280T1 (de)
AU (1) AU2007338404A1 (de)
BR (1) BRPI0720741A2 (de)
CA (1) CA2672718A1 (de)
DE (1) DE602007010038D1 (de)
ES (1) ES2351176T3 (de)
IL (1) IL198630A0 (de)
MX (1) MX2009006158A (de)
WO (1) WO2008077548A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006158A (es) 2006-12-22 2009-06-19 Hoffmann La Roche Derivados de pirimidilo como inhibidores de proteina cinasa.
WO2011025798A1 (en) * 2009-08-28 2011-03-03 Glaxosmithkline Llc Compounds and methods
CA2934199A1 (en) 2013-12-20 2015-06-25 Respivert Limited Urea derivatives useful as kinase inhibitors
EP3730483B1 (de) * 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Klasse von pyrimidinderivaten als kinaseinhibitoren
CN108368060B (zh) * 2017-12-21 2020-09-15 中国科学院合肥物质科学研究院 一类嘧啶类衍生物激酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
TW200406374A (en) * 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
CA2494824A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
PE20051046A1 (es) 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
MX2009006158A (es) 2006-12-22 2009-06-19 Hoffmann La Roche Derivados de pirimidilo como inhibidores de proteina cinasa.

Also Published As

Publication number Publication date
EP2102173B1 (de) 2010-10-20
BRPI0720741A2 (pt) 2014-01-28
EP2102173A1 (de) 2009-09-23
US20100041684A1 (en) 2010-02-18
ES2351176T3 (es) 2011-02-01
CA2672718A1 (en) 2008-07-03
MX2009006158A (es) 2009-06-19
IL198630A0 (en) 2010-02-17
CN101541766B (zh) 2011-07-27
JP2010507573A (ja) 2010-03-11
US8080552B2 (en) 2011-12-20
KR101131400B1 (ko) 2012-04-03
CN101541766A (zh) 2009-09-23
AU2007338404A1 (en) 2008-07-03
KR20090080563A (ko) 2009-07-24
WO2008077548A1 (en) 2008-07-03
ATE485280T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
WO2006066913A3 (en) Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
WO2006066914A3 (en) Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
DE602006020295D1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
ATE500245T1 (de) Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs
SE0402735D0 (sv) Novel compounds
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200639156A (en) New compounds
ATE439361T1 (de) 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
MX2008011769A (es) Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
MX2008001412A (es) Derivados de fenilpiridina, su obtencion y su utilizacion como agentes farmaceuticos.
TW200626149A (en) Tricycles, their manufacture and use as pharmaceutical agents
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200701980A (en) Benzylether derivatives, their manufacture and use as pharmaceutical agents